BioSpace News Archive

Aviceda Therapeutics announced the formation of its European Clinical Advisory Board made up of top internationally recognized thought leaders in retina to provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy secondary to age-related macular degeneration.

CytomX Therapeutics, Inc. today announced the first patient has been dosed in a Phase 1 dose escalation study ( NCT06265688 ) of CX-2051 in patients with advanced solid tumors.

Biora Therapeutics, Inc. announced the issuance of a new patent related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine.

Theriva™ Biologics today announced the presentation of preclinical data demonstrating the potential synergy between lead product candidate, VCN-01 and liposomal irinotecan in a human pancreatic mouse xenograft.

Genetic Technologies Limited is pleased to announce an innovative partnership between GTG, and Humanise Health launching a “Know Your Risk” event featuring the company’s unique Risk Assessment portfolio, to be held at The Langham, Pasadena, California on the 21st of May.

TScan Therapeutics, Inc. today announced the appointment of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer.

Syncromune ® Inc. today announced the presentation of positive results from the SV-102 Phase 1 trial at the American Association for Cancer Research Annual Meeting 2024.

ORIC Pharmaceuticals, Inc. today announced two oral presentations on ORIC-944, a potent and selective allosteric inhibitor of PRC2, and presentation of a new discovery candidate, ORIC-613, an orally bioavailable, potent and selective PLK4 inhibitor, at the 2024 American Association for Cancer Research (AACR) Annual Meeting.

Oryzon Genomics, S.A. announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate a Phase I/II trial with iadademstat plus immune checkpoint inhibitors in first line small cell lung cancer.

SHINE Technologies, LLC, a pioneer in next-generation fusion-based technology, becomes North America’s largest producer of non-carrier added lutetium-177 chloride, a cutting-edge radiopharmaceutical used in precision cancer treatment, with a Drug Master File to the U.S. Food and Drug Administration.